JP2004256527A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004256527A5 JP2004256527A5 JP2004028959A JP2004028959A JP2004256527A5 JP 2004256527 A5 JP2004256527 A5 JP 2004256527A5 JP 2004028959 A JP2004028959 A JP 2004028959A JP 2004028959 A JP2004028959 A JP 2004028959A JP 2004256527 A5 JP2004256527 A5 JP 2004256527A5
- Authority
- JP
- Japan
- Prior art keywords
- acceptable salt
- pde4 inhibitor
- inhibitor according
- pharmacologically acceptable
- pyrazino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 10
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- UQKZERJIZSURJA-UHFFFAOYSA-N 8,9-dimethoxy-6-phenyl-2,3,4,6,11,11a-hexahydro-1h-pyrazino[1,2-b]isoquinoline Chemical compound C1=2C=C(OC)C(OC)=CC=2CC2CNCCN2C1C1=CC=CC=C1 UQKZERJIZSURJA-UHFFFAOYSA-N 0.000 claims 2
- YNRZBYNGFPHYNH-UHFFFAOYSA-N 8,9-dimethoxy-6-phenyl-2,3,4,6,11,11a-hexahydro-1h-pyrazino[1,2-b]isoquinoline;dihydrochloride Chemical compound Cl.Cl.C1=2C=C(OC)C(OC)=CC=2CC2CNCCN2C1C1=CC=CC=C1 YNRZBYNGFPHYNH-UHFFFAOYSA-N 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 208000015100 cartilage disease Diseases 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- -1 pyrazinoisoquinoline compound Chemical class 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000010392 Bone Fractures Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 206010006482 Bronchospasm Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 claims 1
- 206010014950 Eosinophilia Diseases 0.000 claims 1
- 206010017076 Fracture Diseases 0.000 claims 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 claims 1
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 230000007885 bronchoconstriction Effects 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 230000035876 healing Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- CCSONKKTCMHYFI-UHFFFAOYSA-N pyrido[3,4-f]quinoxaline Chemical class C1=NC=C2C3=NC=CN=C3C=CC2=C1 CCSONKKTCMHYFI-UHFFFAOYSA-N 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 208000018464 vernal keratoconjunctivitis Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004028959A JP4352918B2 (ja) | 2003-02-07 | 2004-02-05 | Ｐｄｅ４阻害剤 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003030196 | 2003-02-07 | ||
| JP2004028959A JP4352918B2 (ja) | 2003-02-07 | 2004-02-05 | Ｐｄｅ４阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004256527A JP2004256527A (ja) | 2004-09-16 |
| JP2004256527A5 true JP2004256527A5 (enExample) | 2006-01-19 |
| JP4352918B2 JP4352918B2 (ja) | 2009-10-28 |
Family
ID=33133737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004028959A Expired - Fee Related JP4352918B2 (ja) | 2003-02-07 | 2004-02-05 | Ｐｄｅ４阻害剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4352918B2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6242939B2 (ja) * | 2015-06-11 | 2017-12-06 | 御木本製薬株式会社 | Ｃｔｉｐ２遺伝子発現増強剤 |
-
2004
- 2004-02-05 JP JP2004028959A patent/JP4352918B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20040110763A1 (en) | Pyrazolopyridine compound and pharmaceutical use thereof | |
| JP5422783B2 (ja) | Ｐｉ３キナーゼ阻害剤として使用するキナゾリン−４（３ｈ）−オン誘導体 | |
| JP2005508313A5 (enExample) | ||
| MX2008011369A (es) | Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2. | |
| WO2005021515A3 (en) | Inhibitors of phosphodiesterase type-iv | |
| WO2006064355A3 (en) | Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders | |
| TNSN07251A1 (en) | 2-phenyl-indoles as prostaglandin d2 receptor antagonists | |
| TWI262920B (en) | New 7-azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them | |
| JP2008519794A5 (enExample) | ||
| MX352171B (es) | Sal de hemisulfato de n-(5s,6s,9r)-5-amino-6-(2,3-difluorofenil)-6 ,7,8,9-tetrahidro-5h-ciclohepta[b]piridin-9-il-4-(2-oxo-2,3-dihid ro-1h-imidazo[4,5-b]piridin-1-il)piperidina-1-carboxilato. | |
| JP2010155827A5 (enExample) | ||
| WO2006018718A3 (en) | Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors | |
| HRP20151338T1 (hr) | [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoksi-etil)-4trifluorometoksi-1h-indol-3-il]metanon kao inhibitor triptaze mastocita | |
| JP2011519845A5 (enExample) | ||
| CA2680636A1 (en) | Quinoline derivatives as crth2 receptor ligands | |
| JP2005525388A5 (enExample) | ||
| MY145648A (en) | Dihydrogen phosphate salt of a prostaglandin d2 receptor antagonist | |
| DK2046787T3 (da) | Pyrazolo[3,4-B]pyridin-forbindelser, og deres anvendelse som PDE4-inhibitorer | |
| WO2007130927A3 (en) | Condensed tricyclic compounds as cgrp-receptor antagonists | |
| JP2004256527A5 (enExample) | ||
| WO2006085212A3 (en) | Condensed isoxaline derivatives as inhibitors of phosphodiesterase type-iv | |
| JP2004256528A5 (enExample) | ||
| UA88795C2 (ru) | Гетероциклические соединения, которые применяются для лечения воспалителных и аллергических нарушений | |
| JP2004256526A5 (enExample) | ||
| TR201901449T4 (tr) | Yeni bifenil türevi ve bunun hazırlanmasına yönelik yöntem. |